Can a pregnant woman safely take oseltamivir (Tamiflu) for influenza treatment or prophylaxis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can a Pregnant Woman Take Tamiflu?

Yes, pregnant women can and should take oseltamivir (Tamiflu) when they have influenza or require post-exposure prophylaxis, as the benefits of treatment outweigh the theoretical risks to the fetus. While oseltamivir is classified as Pregnancy Category C (meaning no adequate human studies exist), extensive real-world evidence demonstrates safety, and influenza infection itself poses significant risks to both mother and fetus.

Evidence Supporting Use in Pregnancy

The FDA drug label for Tamiflu states that oseltamivir should be used during pregnancy "only if the potential benefit justifies the potential risk to the embryo or fetus" 1. However, this cautious language reflects the absence of controlled trials rather than evidence of harm. Multiple ACIP guidelines consistently note that "no adverse effects have been reported among women who received oseltamivir during pregnancy or among infants born to such women" 2, 3, 4.

The most compelling safety data comes from large observational studies:

  • A Danish nationwide registry study of 946,176 pregnancies found no evidence of increased risk for congenital malformations (adjusted OR 0.94,95% CI 0.49-1.83), preterm birth, fetal growth restriction, or other adverse outcomes with first-trimester oseltamivir exposure 5

  • A US/Canadian prospective cohort study showed no increased risk of major birth defects (6.7% exposed vs 7.9% unexposed), preterm delivery (HR 0.65), or small-for-gestational-age infants following oseltamivir exposure 6

  • Post-marketing surveillance data from 2,926 maternal exposures showed spontaneous abortion rates of 2.9%, therapeutic abortion rates of 1.8%, and preterm delivery rates of 4.2%—all lower than background population rates 7

  • A Canadian study of 55,355 births found that women taking oseltamivir were actually less likely to have small-for-gestational-age infants (adjusted RR 0.77) 8

Why Treatment Is Critical

Pregnant women face substantially higher risks from influenza infection itself, particularly during the second and third trimesters, including increased hospitalization rates, severe illness, and maternal mortality 9, 10. The virus poses direct threats to both maternal and fetal health that far exceed any theoretical medication risks.

Practical Prescribing Guidance

For treatment of active influenza:

  • Dose: 75 mg orally twice daily for 5 days 1
  • Initiate within 48 hours of symptom onset for maximum benefit
  • Can be taken with or without food (taking with food may reduce nausea) 1

For post-exposure prophylaxis:

  • Dose: 75 mg orally once daily for at least 10 days after exposure 1
  • During community outbreaks: 75 mg once daily for up to 6 weeks 1

Timing considerations: Oseltamivir can be administered at any time during pregnancy (any trimester) 9, 10. Early vaccination during the third trimester is particularly valuable as it provides passive immunity to the newborn during the first months of life when infants are too young for vaccination 9.

Important Caveats

  • Oseltamivir is not a substitute for influenza vaccination. Pregnant women should receive inactivated influenza vaccine (IIV) or recombinant vaccine (RIV) at any time during pregnancy 9, 10, 4

  • The oral suspension formulation contains sorbitol (2g per 75mg dose), which may cause gastrointestinal upset in patients with hereditary fructose intolerance 1

  • Common side effects include nausea (10%) and vomiting (9%), which may be reduced by taking the medication with food 1

  • Monitor for neuropsychiatric events (confusion, abnormal behavior), though these are more commonly reported in children and adolescents 1

Bottom Line

The evidence strongly supports oseltamivir use in pregnancy. The theoretical concerns reflected in the Pregnancy Category C designation have not materialized in extensive real-world experience involving thousands of exposed pregnancies. Given the well-documented dangers of influenza infection during pregnancy and the reassuring safety profile of oseltamivir, treatment should be offered without hesitation when clinically indicated 11, 12.

References

Research

Oseltamivir in pregnancy and birth outcomes.

BMC infectious diseases, 2018

Research

[WHO clinical practice guidelines for influenza: an update].

Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)), 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.